Evidence map›Paper›PMID 22547109›Full record

ArticleBreast cancer research and treatment2012

Pre-clinical studies of Notch signaling inhibitor RO4929097 in inflammatory breast cancer cells.

Bisrat G Debeb, Evan N Cohen, Kimberly Boley, Erik M Freiter, Li Li, Fredika M Robertson, James M Reuben, Massimo Cristofanilli, Thomas A Buchholz, Wendy A Woodward

Abstract read
In one paragraph

Article in Breast cancer research and treatment, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
3.6field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 63 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Signaling pathways and their potential therapeutic utility in esophageal squamous cell carcinoma.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2022
    Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Rethinking Gamma-secretase Inhibitors for Treatment of Non-small-Cell Lung Cancer: Is Notch the Target?Clinical cancer research : an official journal of the American Association for Cancer Research · 2018
    Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Bisrat G DebebDepartment of Radiation Oncology, Unit 1202, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA.
Evan N Cohen
Kimberly Boley
Erik M Freiter
Li Li
Fredika M Robertson
James M Reuben
Massimo Cristofanilli
Thomas A Buchholz
Wendy A Woodward
Cancer Research Center · USThe University of Texas MD Anderson Cancer Center · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
CTSA: K12 COMPONENTKL2RR024149 · NCRR · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI MCPHERSON, DAVID D · 2006 to 2011
$6.7M
Human Breast Cancer Stem Cell SurrogatesR01CA138239 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI CRISTOFANILLI, MASSIMO, REUBEN, JAMES MARTIN · 2008 to 2012
$2.8M
NCI NIH HHS P30 CA016672NCI NIH HHS R01 CA138239NCI NIH HHS R01CA138239-01NCRR NIH HHS KL2 RR024149
6 · The paper itself

Abstract

Basal breast cancer, common among patients presenting with inflammatory breast cancer (IBC), has been shown to be resistant to radiation and enriched in cancer stem cells. The Notch pathway plays an important role in self-renewal of breast cancer stem cells and contributes to inflammatory signaling which promotes the breast cancer stem cell phenotype. Herein, we inhibited Notch signaling using a gamma secretase inhibitor, RO4929097, in an in vitro model that enriches for cancer initiating cells (3D clonogenic assay) and conventional 2D clonogenic assay to compare the effect on radiosensitization of the SUM149 and SUM190 IBC cell lines. RO4929097 downregulated the Notch target genes Hes1, Hey1, and HeyL, and showed a significant reduction in anchorage independent growth in SUM190 and SUM149. However, the putative self-renewal assay mammosphere formation efficiency was increased with the drug. To assess radiosensitization of putative cancer stem cells, cells were exposed to increasing doses of radiation with or without 1 μM RO4929097 in their standard (2D) and self-renewal enriching (3D) culture conditions. In the conventional 2D clonogenic assay, RO4929097 significantly sensitized SUM190 cells to ionizing radiation and has a modest radiosensitization effect in SUM149 cells. In the 3D clonogenic assays, however, a radioprotective effect was seen in both SUM149 and SUM190 cells at higher doses. Both cell lines express IL-6 and IL-8 cytokines known to mediate the efficacy of Notch inhibition and to promote self-renewal of stem cells. We further showed that RO429097 inhibits normal T-cell synthesis of some inflammatory cytokines, including TNF-α, a potential mediator of IL-6 and IL-8 production in the microenvironment. These data suggest that additional targeting agents may be required to selectively target IBC stem cells through Notch inhibition, and that evaluation of microenvironmental influences may shed further light on the potential effects of this inhibitor.

Indexed as

Aldehyde DehydrogenaseAmyloid Precursor Protein SecretasesAntigens, CDAntineoplastic AgentsBenzazepinesCell Line, TumorCell MovementCell ProliferationCell SurvivalDrug Screening Assays, AntitumorFemaleFluorocarbonsGene ExpressionHumansInflammation MediatorsInflammatory Breast Neoplasms2,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamideAldehyde DehydrogenaseAmyloid Precursor Protein SecretasesAntigens, CDAntineoplastic AgentsBenzazepinesFluorocarbonsIL6 protein, humanInflammation MediatorsInterleukin-6Interleukin-8Radiation-Sensitizing AgentsReceptors, Antigen, T-CellReceptors, Notch

Identifiers

PMID22547109
PMCPMC4545650
OpenAlexW2046483038

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.